Providing diagnostics due diligence

Challenge: A major European venture capital investor needed to analyze the business plan of a novel point-of-care diagnostics company.
Learn More

Preclinical due diligence of novel live biotherapeutic

Challenge: An early-stage venture fund asked Alacrita to review the opportunity for reinvestment in a biotech developing a novel live biotherapeutic for the treatment of inflammatory bowel disorders...
Learn More

Due diligence for a new imaging technology

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.
Learn More

Providing an oncology cell therapy reality check

Challenge: A venture capital investor needed a reality check on a clinical stage cancer biologic prior to a proposed $10m investment with a very short deadline.
Learn More

Providing biotech due diligence of a Phase lll oncology program

Challenge: A major pharmaceutical company asked us for support in the due diligence and assessment of a Phase III in-licensing opportunity. The drug in question had met its primary endpoint in a...
Learn More

Providing in-licensing due diligence

Challenge: A pharma company needed help conducting due diligence on an in-licensing/acquisition candidate for a Phase IIb respiratory drug.
Learn More

Vendor due diligence of a regulatory dossier

Challenge: A biotech company with a novel oral drug delivery technology platform was looking to out-license its lead asset, a reformulated generic therapeutic in a new, non-opioid pain, indication,...
Learn More

Oncology due diligence

Challenge: Alacrita was engaged by a strategic investor to conduct initial due diligence on a new EGFR therapeutic strategy in oncology.
Learn More

Alzheimer's due diligence for strategic investor

Challenge:  Alacrita was engaged by a strategic investor to conduct initial due diligence on a novel observation and potential product opportunity in Alzheimer’s disease.
Learn More

Due diligence on generic therapeutic

Challenge A private investment firm was seeking an independent reality-check on a potential investment in a pharmaceutical company that had recently in-licensed a generic therapeutic asset. The firm...
Learn More

Dermatology due diligence and valuation

Challenge Alacrita’s pharma consultants were engaged to conduct a due diligence and valuation of a Phase II dermatology asset.
Learn More

Strategic and operational support for a start-up oncology company

Challenge A start-up company was planning to license an immunomodulatory product from a European pharmaceutical company. The therapy had been unsuccessfully tried in allergic disorders, but the...
Learn More
Content not found